Sunitinib, sold under the brand name Sutent, is an anti-cancer medication. It is a small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor...

effectiveness of everolimus in carcinoid tumors have not been established. sunitinib (Sutent) is labeled for treatment of progressive, well-differentiated...

randomized study of zanzalintinib in combination with nivolumab versus sunitinib in patients with advanced or metastatic non-clear cell RCC (nccRCC). Sharma...

(NSCLC). Sunitinib is an oral drug that inhibits the phosphorylation of all the VEGF receptors, PDGFR-ß, KIT FLT3, CSF1R and GDNF. Sunitinib is used in...

approved within the past ten years. These treatments are: Nivolumab Axitinib Sunitinib Cabozantinib Everolimus Lenvatinib Pazopanib Bevacizumab Sorafenib Tivozanib...

inhibitor that is effective both as a senolytic and as therapy for CML. Sunitinib, an inhibitor of the receptors for FGF, PDGF and VEGF is also based on...

multiple-tyrosine-kinase inhibitor sunitinib (marketed as Sutent) can be considered.: 26 and 31  The effectiveness of imatinib and sunitinib depends on the genotype...

shut down in 2003, after developing the pioneering kinase inhibitor drug sunitinib (Sutent). Sugen was founded in 1991 in Redwood City, California, by veteran...

cytokine therapy (IL-2, interferon), kinase inhibitors (temsirolimus, sunitinib, sorafenib, pazopanib) and anti-angiogenic therapies (bevacizumab). "Clear...

small molecules that inhibit the tyrosine kinases stimulated by VEGF: sunitinib, sorafenib, axitinib, and pazopanib (some of these therapies target VEGF...

MedlinePlus. Clinical trial number NCT01835158 for "Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced...

phosphate. It was developed by SUGEN as SU11654, a sister compound to sunitinib, which was later approved for human therapies. Toceranib is a tyrosine...

removal and is causing symptoms, targeted therapy with everolimus or sunitinib can reduce symptoms and slow progression of the disease. Standard cytotoxic...

trial number NCT02231749 for "Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate...

jobs, and several programs were transferred to Pfizer. These included sunitinib (Sutent), a cancer medication which was approved for human use by the...

L01EN02 Pemigatinib L01EN03 Infigratinib L01EN04 Futibatinib L01EX01 Sunitinib L01EX02 Sorafenib L01EX03 Pazopanib L01EX04 Vandetanib L01EX05 Regorafenib...

stabilizers, amiodarone, interferon alpha, tyrosine kinase inhibitors such as sunitinib Central hypothyroidism Lesions compressing the pituitary (pituitary adenoma...

Masitinib Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL)...

Masitinib Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL)...

treatment for patients with advanced kidney cancer after failure of either sunitinib or sorafenib" (Press release). Novartis. 30 March 2009. Archived from...

c-MET, making ASPS sensitive to small-molecule kinase inhibitor such as sunitinib. Current clinical trials are exploring the utility of kinase inhibitors...

Retrieved 20 July 2023. "A Study of Abemaciclib in Combination With Sunitinib in Metastatic Renal Cell Carcinoma". www.clinicaltrials.gov. Retrieved...

Masitinib Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL)...

Masitinib Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL)...

vinblastine, vincristine, vindesine, imatinib, irinotecan, sorafenib, sunitinib, vemurafenib, temsirolimus, anastrozole, gefitinib; azole antifungals:...

reaction of esters with hydrazine: An applied example is a synthesis of sunitinib begins by mixing 5-fluoroisatin slowly into hydrazine hydrate. After 4...

Masitinib Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL)...

phase 3 study (Checkmate 9ER) that showed this regimen to be superior to sunitinib, which led to its FDA approval in January 2021. He also co-led with Robert...

Masitinib Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL)...

the availability of tyrosine kinase inhibitors, such as imatinib and sunitinib that can block the activity of c-KIT pharmacologically. It is expected...